Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

Barchart · 3d ago

SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billion, representing a year-over-year increase of 5.26%. Product sales revenue was RMB21.48 billion, up 2.52% year-over-year. Net profit attributable to shareholders of the Company was RMB6.92 billion, up 20.38% year-over-year.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.